novartis_outside_1

Novartis’ Cosentyx gets European go-ahead in paediatric plaque psoriasis

pharmafile | August 3, 2020 | News story | Sales and Marketing |  Cosentyx, Europe, Novartis, pharma, psoriasis 

Novartis’ interleukin-17A (IL-17A) inhibitor Cosentyx (secukinumab) has chalked up approval from the European Commission (EC) for the treatment of patients between the ages of six and 18 with moderate-to-severe plaque psoriasis.

The ruling was secured on the back of data from two Phase 3 studies which demonstrated the safety and efficacy of low and high dosages (75-150mg and 75-300mg) in improving skin symptoms and quality of life. According to this latest approval, the recommended dose for children weighing up to 50 kg is 75 mg, and 150 mg for children 50 kg and over.

“Psoriasis is a life-long debilitating disease that significantly impacts children’s quality of life, both physically and emotionally. There are only a few approved treatment options available for the paediatric population and so it is important to broaden the adult therapeutic options out to children when possible,” said Professor Christine Bodemer, Head of the Department of Dermatology, Necker–Enfants Malades Hospital. “This approval means Cosentyx is now available in Europe for children and adolescents, and will provide an additional option to quickly gain relief from their symptom burden and to significantly improve their quality of life.”

Advertisement

Novartis said it was already at work in order to make the therapy available to eligible patients “as quickly as possible”.

Matt Fellows

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

Scotland starts newborn screening for SMA

As part of a two-year evaluation funded by the Scottish government and Novartis, Scotland will …

The Gateway to Local Adoption Series

Latest content